US equities |
NVDA $176.49 ▲+4.50% MU $822.58 ▲+13.44% AMD $560.75 ▲+8.84% SNDK $1,003.10 ▲+16.64% SPCX $142.09 ▼-0.70% MSFT $521.35 ▼-2.22% CRWV $61.32 ▲+25.84% TSLA $392.51 ▲+3.35%
FinancialContent

Innovation Pharmaceuticals Inc (OP:IPIX)

0.0002 UNCHANGED
Delayed Quote Updated: 9:37 AM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,386
Open 0.0002
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0002
Today's Range 0.0002 - 0.0002
52wk Range 0.0001 - 0.0500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property

Performance

52-Week Range 99.6% below 52-week high
0.0002
0.0052W Low 0.0552W High
1 Week 88.9% below 1-week high
0.001W Low 0.001W High

Innovation Pharmaceuticals Inc (IPIX) traded between $0.00 and $0.05 over the past 52 weeks and last traded at $0.00, 99.6% below its 52-week high. Over the past week it ranged between $0.00 and $0.00.

Past 12 Months
N/A
N/A
-75.0%
-33.3%
-80.0%
-71.4%
1W  
1M  
3M -$0.00
6M -$0.00
YTD -$0.00
1Y -$0.00

IPIX was -71.4% over the past year, -33.3% over six months, -80.0% year to date.

12 Months vs Market
IPIX
-71.4%
DIA
+10.4%
SPY
+11.6%
QQQ
+11.3%
IWM
+16.0%

Over the past 12 months IPIX returned -71.4% versus DIA (Dow) +10.4%, SPY (S&P 500) +11.6%, QQQ (Nasdaq 100) +11.3% and IWM (Russell 2000) +16.0%.

Volume & Liquidity 0.01× 3-mo avg
Today 2,386 3-mo avg 231.9K
1W
278.1K
1M
290.4K
3M
231.9K
6M
224.5K
YTD
190.3K
1Y
231.2K

IPIX most recently traded 2,386 shares against a 3-month average daily volume of 231.9K.

More News

Read More
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Via NewMediaWire
News headline image
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
Via NewMediaWire
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Via NewMediaWire
News headline image
Scientific Poster on Innovation Pharmaceuticals Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference
Via NewMediaWire
News headline image
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"
Via NewMediaWire
News headline image
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium
Via ACCESSWIRE
News headline image
Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
Via ACCESSWIRE
News headline image
Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox
Via ACCESSWIRE
News headline image
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
Via ACCESSWIRE
News headline image
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
These OTC Securities Had the Most Trading Activity in November ↗
Via Benzinga
News headline image
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Provides Brilacidin Program Update
From Innovation Pharmaceuticals Inc.
Via AccessWire
News headline image
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
From Innovation Pharmaceuticals Inc.
Via AccessWire

Frequently Asked Questions

Is Innovation Pharmaceuticals Inc publicly traded?
Yes, Innovation Pharmaceuticals Inc is publicly traded.
What exchange does Innovation Pharmaceuticals Inc trade on?
Innovation Pharmaceuticals Inc trades on the OTC Traded
What is the ticker symbol for Innovation Pharmaceuticals Inc?
The ticker symbol for Innovation Pharmaceuticals Inc is IPIX on the OTC Traded
What is the current price of Innovation Pharmaceuticals Inc?
The current price of Innovation Pharmaceuticals Inc is 0.0002
When was Innovation Pharmaceuticals Inc last traded?
The last trade of Innovation Pharmaceuticals Inc was at 11/11/26 09:37 AM ET